<DOC>
	<DOCNO>NCT00000727</DOCNO>
	<brief_summary>To determine drug combination sulfamethoxazole-trimethoprim ( SMX-TMP ) , give mouth , drug pentamidine ( PEN ) , give inhaled aerosol , effective preventing relapse Pneumocystis carinii pneumonia ( PCP ) give patient recover first episode PCP give zidovudine ( AZT ) treat primary HIV infection . AZT prolongs survival patient AIDS decrease occurrence opportunistic infection PCP . However , PCP recur 43 percent patient receive AZT , indicate need treatment reduce relapse rate . The two medication test study , SMX/TMP aerosolize PEN , also partially effective prevent recurrence PCP . It hop combination AZT medication effective AZT one medication alone .</brief_summary>
	<brief_title>A Controlled Comparative Trial Sulfamethoxazole-Trimethoprim Versus Aerosolized Pentamidine Secondary Prophylaxis Pneumocystis Carinii Pneumonia AIDS Patients Receiving Azidothymidine ( AZT )</brief_title>
	<detailed_description>AZT prolongs survival patient AIDS decrease occurrence opportunistic infection PCP . However , PCP recur 43 percent patient receive AZT , indicate need treatment reduce relapse rate . The two medication test study , SMX/TMP aerosolize PEN , also partially effective prevent recurrence PCP . It hop combination AZT medication effective AZT one medication alone . Patients receive standard dose AZT study entry . Low body weight patient receive AZT low dose . Patients randomly assign one two medication intend prevent recurrence PCP . Patients assign SMX/TMP take 1 capsule contains drug day 1 year . Patients assign PEN 1 aerosol treatment every 4 week 1 year . Blood drawn interval order estimate blood level drug detect adverse effect drug . Note : Earlier version protocol reflect original design 3-arm study compare aerosolize PEN , SMX/TMP , pyrimethamine-sulfadoxine secondary prophylaxis PCP AIDS patient receive AZT . In order reduce effective sample size permit completion accrual reasonable period time , pyrimethamine - sulfadoxine arm study discontinue . Patients randomize arm continue study original randomize therapy . Management patient follow describe SMX/TMP late protocol version . AMENDED : Lower dose AZT allow .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Pentamidine</mesh_term>
	<criteria>Inclusion Criteria Patients must fulfill follow criterion : Randomization within 10 week complete therapy Pneumocystis carinii pneumonia ( PCP ) . Ability tolerate oral aerosolize therapy time randomization . Life expectancy &gt; 4 month . Concurrent Medication : Allowed : Inhaled bronchodilator cough bronchospasm relate aerosolized pentamidine treatment . Aspirin modest dos . Ibuprofen modest dos . Acetaminophen modest dos . Erythropoietin management anemia . Allowed treat opportunistic infection study : Acyclovir . Ketoconazole . Amphotericin B. Nystatin . Clotrimazole . Also allow : Ganciclovir ( DHPG ) maintenance therapy lifethreatening sightthreatening cytomegalovirus retinitis ( CMV retinitis ) infection . Zidovudine ( AZT ) must discontinue acute induction phase treatment restart maintenance therapy introduce . Concurrent Treatment : Allowed : Local radiation therapy Kaposi 's sarcoma . Prior Medication : Allowed : Primary prophylactic therapy prior Pneumocystis carinii pneumonia ( PCP ) episode . Risk Behavior : Allowed : Patients maintain methadone maintenance program per local investigator 's judgment . Exclusion Criteria Active drug alcohol abuse would impair performance study subject . Concurrent Medication : Excluded : Famotidine . Any medication suspect interference metabolism zidovudine . Flurazepam . Chronic probenecid . Phenobarbital . Phenytoin . Experimental therapy , except note . Chronic oral bronchodilator start patient order maintain aerosolize pentamidine exhibit pulmonary toxicity . Prior Medication : Excluded 30 patient undergo pharmacokinetic study : Zidovudine ( AZT ) time . Excluded within 7 day study entry 30 patient undergo pharmacokinetic study : Trimethoprim / sulfamethoxazole . Pyrimethamine / sulfadoxine . Aerosolized pentamidine . Excluded : Pentamidine route original infection . Prophylactic therapy Pneumocystis carinii pneumonia ( PCP ) discontinuation acute treatment study entry . Prior Treatment : Excluded within 2 week study entry : Transfusions blood red blood cell . Patients may follow symptom disease : Known treatmentlimiting hypersensitivity sulfonamide , trimethoprim , pyrimethamine , pentamidine , zidovudine ( AZT ) , especially limited , exfoliative dermatitis , erythema multiforme , StevensJohnson syndrome . Development severe hypoglycemia ( serum glucose &lt; 50 mg/dl pentamidine therapy ) . History neoplasms basal cell carcinoma skin carcinoma situ cervix , mucocutaneous Kaposi 's sarcoma . Known visceral Kaposi 's sarcoma . Known glucose6phosphate dehydrogenase ( G6PD ) deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Sulfadoxine</keyword>
	<keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Pentamidine</keyword>
	<keyword>Pyrimethamine</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Administration , Inhalation</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Aerosols</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
</DOC>